Andere Sprachen Cogent Biosciences, Inc.

Aktien

A2QJAY

US19240Q2012

COGT

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
6.02 ^USD	+0.17%		-15.45%	+2.38%

26.02.	COGENT BIOSCIENCES, INC. : Citigroup behält die Bewertung Kaufen bei	ZM
26.02.	Cogent Biosciences, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)	18.04.
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor	09.04.
North American Morning Briefing : Stock Futures -2-	27.02.
Cogent Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26.02.
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results	26.02.
Cogent Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26.02.
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis	22.02.
Cogent Biosciences Announces Positive Part 1B Data from Summit Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis	22.02.
Top Midday Gainers	14.02.
Cogent Biosciences Launches $225 Million Private Placement; Shares Jump	14.02.
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement	14.02.
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting	05.02.
Cogent Biosciences Expects Certain Milestones for Bezuclastinib Trials in 2024	09.01.
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics	09.01.
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference	02.01.
North American Morning Briefing : Traders Eye -2-	12.12.
Sector Update: Health Care Stocks Higher Late Afternoon	11.12.
Top Midday Decliners	11.12.
Sector Update: Health Care Stocks Rise Monday Afternoon	11.12.
Cogent Biosciences Says Phase 2 Trial of Bezuclastinib Showed 4 Related Serious Adverse Events; Shares Down	11.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Cogent Biosciences, Inc.

Aktien

A2QJAY

US19240Q2012

COGT

Andere Sprachen

Filter